Targeting the TNF-α pathway in sarcoidosis

@article{Antoniu2010TargetingTT,
  title={Targeting the TNF-$\alpha$ pathway in sarcoidosis},
  author={S. Antoniu},
  journal={Expert Opinion on Therapeutic Targets},
  year={2010},
  volume={14},
  pages={21 - 29}
}
  • S. Antoniu
  • Published 2010
  • Medicine
  • Expert Opinion on Therapeutic Targets
Importance of the field/Significance: Sarcoidosis is a granulomatous disease with various organ manifestations in which TNF-α has been demonstrated to play a major pathogenic role. The existing conventional therapies are not always able to minimize TNF-α-driven inflammation and other approaches should be used. Areas covered in this review: TNF-α roles in sarcoid inflammation and granuloma formation are reviewed based on the literature published in the last two decades and the therapies able to… Expand

Topics from this paper

Cytokine modulators in the treatment of sarcoidosis
TLDR
This review focuses on recent advances in anti-TNFα agents and cytokine modulators for the treatment of sarcoidosis and their therapeutic prospects. Expand
Practical eminence and experience-based recommendations for use of TNF-α inhibitors in sarcoidosis.
TLDR
Practical recommendations for the use of TNF-α inhibitor use, with emphasis on indications, dosage and discontinuation regimens, have been developed to support the clinician in the management of refractory sarcoidosis patients. Expand
A Rare Adverse Effect of Anti-Tumor Necrosis Factor Alpha Therapy: Sarcoidosis.
TLDR
An ankylosing spondylitis patient who was diagnosed as sarcoidosis during the period of etanercept usage is reported to be kept in mind during anti-TNF-a therapy. Expand
No impact of tumor necrosis-factor antagonists on the joint manifestations of sarcoidosis
TLDR
TNF antagonists allowed significant steroid sparing and were well tolerated, but do not seem to be effective against sarcoidosis joint involvement. Expand
Therapeutic approach of hepatic sarcoidosis
TLDR
The importance of an appropriate therapeutic approach of sarcoidosis patients with hepatic involvement is illustrated, stressing the need for future studies to evaluate treatment options to avoid disease progression and hepatic complications. Expand
The clinical and immunologic features of pulmonary fibrosis in sarcoidosis.
TLDR
Elucidating the natural history of sarcoidosis-associated PF will inform the understanding of the fundamental derangements, and will enhance prognostication and the development of therapeutic strategies. Expand
C URRENT OPINION Therapeutic approach of hepatic sarcoidosis
TLDR
This review analyses published data on the pharmacological treatment of hepatic sarcoidosis to find beneficial effects of prednisone and the augmentation of cytotoxic and anti-tumor necrotic factor-a (TNF-a) therapy, but because of small sample sizes, no meaningful conclusions could be drawn. Expand
Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis
TLDR
The case of a 52-year-old woman with psoriatic arthritis who developed multisystem sarcoidosis while being treated with secukinumab (anti-interleukin-17A) therapy is described, which, to the authors' knowledge, is the first such case. Expand
Aetiology and clinical phenotype still seem distant in sarcoidosis
TLDR
The article probes this notion of immunobiological predisposition by examining the prevalence of atopy/asthma in sarcoidosis, and the degree of mutual exclusivity between T-helper 1 cells (TH1) and T- Helper 2 Cells (TH2) predominant cytokine patterns, and finding an absence of T-cell skewing. Expand
Review for Disease of the Year: Immunopathogenesis of Ocular Sarcoidosis
TLDR
This review deals with immunologic sequences that lead to the formation of sarcoid granulomas and explores the immunopathogenesis of ocular inflammation seen in patients with Sarcoidosis. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 79 REFERENCES
Treatment of therapy-resistant sarcoidosis with adalimumab
TLDR
Successful treatment using adalimumab, a human recombinant immunoglobulin (Ig) G1 anti-TNF monoclonal antibody is described, which indicates this cytokine plays a crucial role in granulomatous inflammation, e.g., in mycobacterial diseases. Expand
Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them.
TLDR
A stepwise approach is proposed to increase the likelihood of disease improvement for patients who experience an inadequate response to an anti-TNF agent as well as the relative benefits and side effects of the three anti- TNF biological agents for treating sarcoidosis. Expand
Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis.
TLDR
In patients with progressive stage II or III pulmonary sarcoidosis, etanercept was frequently associated with early or late treatment failure, and data would not support the design of a large multicenter randomized trial comparing etanenercept with conventional corticosteroid therapy. Expand
Infliximab for refractory sarcoidosis.
  • R. Baughman, E. Lower
  • Medicine
  • Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
  • 2001
TLDR
Infliximab was associated with significant improvement in chronic sarcoidosis, and the index lesion was lupus pernio, which significantly improved with infliximab. Expand
Sarcoidosis: immunopathogenetic concepts and their clinical application.
TLDR
Using these approaches methotrexate, pentoxifylline and thalidomide have been identified as drugs which effectively suppress sarcoid inflammation and the serum level of soluble interleukin-2 receptors has been delineated to be a serum marker of sarcoids inflammation. Expand
Role of TNFα in pulmonary pathophysiology
TLDR
Despite some immunological side effects, anti-TNFα therapeutic strategies represent an important breakthrough in the treatment of inflammatory diseases and may have a role in pulmonary diseases characterized by inflammation and cell death. Expand
Inter-relationship between tumour necrosis factor-alpha (TNF-α) and TNF soluble receptors in pulmonary sarcoidosis
TLDR
The results indicate that TNF-α bioactivity may be inhibited by increased soluble T NF-R in the lungs of subjects with sarcoidosis, and this inhibition may be greater in patients with stage I sarcoidsosis than in those with stage II/III disease. Expand
Refractory sarcoidosis responding to infliximab.
TLDR
A case of refractory sarcoidosis, involving the lung, eyes, skin, and heart, which flared despite aggressive therapy is reported, and oculocutaneous Sarcoid dramatically improved after treatment with the anti-TNF antibody infliximab. Expand
The use of TNF-alpha blocking agents in rheumatoid arthritis: an update.
TLDR
These new biological therapies blocking TNF-alpha undoubtedly constitute a considerable advancement in the management of RA, but careful evaluation at the initiation of the treatment and long-term surveillance of the patients receiving such drugs remains necessary. Expand
Immunology and pathophysiology
TLDR
An overview of the available knowledge concerning the mechanisms leading to the inflammatory processes that occur at common sites of involvement in sarcoidosis is provided and a detailed description of the cellular interactions that govern the dynamics of granuloma formation is included. Expand
...
1
2
3
4
5
...